| News

Pfizer acquires Basel-based Therachon

09.05.2019

U.S. pharmaceutical company Pfizer is acquiring Basel biotech Therachon for US$ 340 million. Additional payments of US$ 470 million may also be received on the achievement of key milestones. Therachon has developed a drug for the treatment of a form of short-limbed dwarfism.

Drug discovery (img: motorolka_10/shutterstock)

Therachon Holding AG has developed products for the treatment of achondroplasia and short bowel syndrome. These include product candidate TA-46 for the treatment of achondroplasia, “a genetic condition and the most common form of short-limbed dwarfism”, as was reported in a press release from Pfizer. The U.S. pharmaceutical company is acquiring Basel-based Therachon for US$ 340 million and has also committed itself to an additional US$ 470 million in payments contingent on the achievement of key milestones in the development and commercialization of TA-46. Prior to the closing of the transaction, Therachon will “spin-off its apraglutide development program into a separate, independent company”. This program for short bowel syndrome is currently in Phase 2 development. Pfizer will be involved in this company via Pfizer Ventures.

“At Pfizer, our strategy is focused on advancing the most promising science in the world, regardless of whether it is found inside or outside of our labs,” commented Mikael Dolsten, Chief Scientific Officer and President of Worldwide Research, Development and Medical at Pfizer. “By acquiring Therachon, we hope to leverage Pfizer’s leading scientific and development capabilities to more rapidly advance this potentially promising therapy for people with achondroplasia.”

Achondroplasia currently affects approximately 250,000 people worldwide and there are currently no approved treatments. TA-46 developed by Therachon has completed clinical phase 1 and received Orphan Drug Designation from the European Medicines Agency and the U.S. Food and Drug Administration. “Therachon is a great example of the value that can be built from cutting edge European science,” said Tom Woiwode, Chairman and Managing Director of Versant Ventures, one of the founding investors in Therachon. Luca Santarelli, CEO of Therachon, adds: “We look forward to Pfizer continuing to develop TA-46 in the hope that it will significantly improve the lives of children suffering from achondroplasia.”

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Yokogawa establishes innovation center in Allschwil

The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.

Read More
Basel Area Business & Innovation, Innovation, Invest

Basel gains new biotech in Bright Peak

Versant Ventures has made a US$35 million Series A funding commitment to Bright Peak Therapeutics and has now announced the debut of this biotech. It will operate in Basel and San Diego.

Read More
Basel Area Business & Innovation, Innovation, Switzerland Innovation Park

Robots from Basel set to revolutionize surgery

The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.

Read More
Basel Area Business & Innovation, Innovation

T3 Pharma raises over 25 million Swiss francs

T3 Pharmaceuticals AG has closed its third financing round, raising over 25 million Swiss francs. The Basel-based startup has developed a bacterial cancer therapy that it now intends to progress to clinical trials.

Read More
Basel Area Business & Innovation, Innovation

Versameb raises 6 million Swiss francs

The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.

Read More
Basel Area Business & Innovation, Innovation

Genedata accelerating drug development

Genedata, a Basel IT company specializing in the life sciences sector, has agreed a collaboration with Thermo Fisher. The integration of their two platforms will help accelerate the development of drugs.

Read More
Basel Area Business & Innovation, Innovation, Invest

Basel is “probably the most productive life sciences location in the world”

Two thirds of the value added attributable to the pharmaceutical industry as a whole in Switzerland is generated in the Basel Area, as revealed by an Interpharma report. However, the region also shines in an international comparison. Interpharma CEO René Buholzer regards it as “probably the most productive life sciences location in the world”.

Read More
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Basel Area cantons publish joint economic report

The cantons of Basel-Landschaft, Basel-Stadt and Jura have just published their first joint Economic Report. The fundamental environment is described as “good” in the report.

Read More
Basel Area Business & Innovation, Innovation

Resistell receives high-level EU grant

Resistell AG, based in Muttenz in the canton of Basel-Landschaft, has received a grant of up to 2.5 million euros and additional equity capital financing from a European fund with the aim of accelerating innovation. The company is developing the world’s fastest test against antibiotic resistance.

Read More
Novartis Campus
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Switzerland Innovation Park Basel Area Site Novartis Campus

We are happy to present our latest addition to the Switzerland Innovation Park Basel Area: Our site on the Novartis Campus dedicated to digital health provides a focal point to a unique community of digital healthcare experts.

Read More
1 2 3 19

Do you have a question? We'd like to hear from you.